Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Peregrine Pharmaceuticals
Peregrine Pharmaceuticals officials describe recent developments
April 11th, 2007
Peregrine Pharmaceuticals officials describe recent developments. This trend article is an immediate alert from NewsRx to identify the most recent news developments at Peregrine Pharmaceuticals. Report 1: Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company developing targeted therapeutics for the treatment of cancer and hepatitis C virus (HCV) infection, today reported preliminary top-line results from a Phase lb study of its targeted immunotherapy bavituximab in patients with chronic HCV infection. The repeat dose, multi-center open label study was designed to assess the safety, distribution and pharmacokinetic properties of...
Source: Medical Patent Law Weekly (2007-04-11)
|
